Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 180,273
  • Shares Outstanding, K 45,988
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,800 K
  • 60-Month Beta 1.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.48
  • Low Estimate -0.63
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +16.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.42 +12.87%
on 01/13/20
5.58 -30.82%
on 12/18/19
-0.94 (-19.58%)
since 12/17/19
3-Month
2.75 +40.36%
on 11/12/19
13.58 -71.58%
on 10/23/19
-8.42 (-68.57%)
since 10/17/19
52-Week
2.75 +40.36%
on 11/12/19
26.98 -85.69%
on 01/18/19
-22.75 (-85.49%)
since 01/17/19

Most Recent Stories

More News
Applied Genetic Stock Up on Favorable Eye Therapy Study Data

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

AGTC : 8.16 (+0.37%)
SRPT : 127.90 (-1.84%)
RGNX : 48.19 (-1.85%)
SLDB : 3.86 (-1.53%)
Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer candidate for the treatment of Duchenne...

SLDB : 3.86 (-1.53%)
Sarepta Signs Gene Therapy Agreement With Roche for $1.15B

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone...

RHHBY : 35.3400 (-15.35%)
SRPT : 127.90 (-1.84%)
SLDB : 3.86 (-1.53%)
BOLD : 59.97 (-0.02%)
Solid Biosciences Provides Data Update from SGT-001 Development Program

- Demonstrated expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit for patients with Duchenne

SLDB : 3.86 (-1.53%)
Options Traders Expect Huge Moves in Solid Biosciences (SLDB) Stock

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

SLDB : 3.86 (-1.53%)
Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up

Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.

PFE : 40.51 (-0.25%)
SRPT : 127.90 (-1.84%)
BOLD : 59.97 (-0.02%)
SLDB : 3.86 (-1.53%)
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

GILD : 62.98 (-0.35%)
BIIB : 285.50 (-0.22%)
XLRN : 56.14 (-0.20%)
CELG : 108.24 (+0.10%)
AMRN : 19.91 (-0.75%)
SLDB : 3.86 (-1.53%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Solid Biosciences Inc. - SLDB

Pomerantz LLP is investigating claims on behalf of investors of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB). Such investors are advised to contact Robert S. Willoughby...

SLDB : 3.86 (-1.53%)
Solid Biosciences Provides SGT-001 Program Update

Solid Biosciences Inc. (Nasdaq: SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the company that IGNITE DMD, its Phase I/II...

SLDB : 3.86 (-1.53%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

SLDB : 3.86 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade SLDB with:

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

2nd Resistance Point 4.13
1st Resistance Point 4.03
Last Price 3.86
1st Support Level 3.82
2nd Support Level 3.71

See More

52-Week High 26.98
Fibonacci 61.8% 17.72
Fibonacci 50% 14.86
Fibonacci 38.2% 12.01
Last Price 3.86
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar